FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression
Human Mutation · 2025
DOI: 10.1155/humu/5947612 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, 2025. Verfasst von Yu Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xiangya Hospital, Central South University, Changsha, China, csu.edu.cn. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Apoptosis, Curcumin, Proto-Oncogene Proteins c-bcl-6. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Bladder cancer represents one of the most common malignancies globally, posing a severe threat to human health. Through compound library screening, we identified tetramethylcurcumin (FLLL31), a diketone analog of curcumin, as exhibiting significant inhibitory effects on the malignant biological behaviors of bladder cancer cells. Although possessing diverse biological activities, the application of FLLL31 in bladder cancer has not been reported previously. To investigate the function and mechanism of FLLL31, we assessed its impact on the proliferation, migration, and invasion of T24 and 5637 cells using CCK‐8, EdU, colony formation, and Transwell. The in vivo efficacy of FLLL31 was evaluated by intraperitoneal injection in BALB/c‐nu mice bearing subcutaneous xenografts. Utilizing RNA‐seq, qRT‐PCR, Western blotting, electron microscopy, flow cytometry, and JC‐1 staining, we further explored the mechanism underlying FLLL31′s inhibition of malignant behaviors in bladder cancer cells. The results demonstrate that FLLL31 inhibits malignant bladder cancer behaviors by inducing apoptosis via the FOXO4/BCL6 axis. This pathway was further confirmed by the observation that lentiviral knockdown of either FOXO4 or BCL6 attenuated FLLL31‐induced apoptosis. Mechanistically, FLLL31 upregulates FOXO4, leading to increased BCL6 expression. This subsequently suppresses the antiapoptotic protein Bcl‐xL, thereby triggering apoptosis. These findings highlight the therapeutic potential of FLLL31 for bladder cancer and identify the FOXO4/BCL6 pathway as a promising novel target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Xiangya Hospital, Central South University, Changsha, China, csu.edu.cn.
- Provincial Laboratory for Diagnosis and Treatment of Genitourinary System Disease, Changsha, China.
ORCID-Profile: Yu Han, Jingxuan Peng, Wenjie Yan, Ziqiang Wu, Zhengyan Tang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Han, Y., Peng, J., Yan, W., Wu, Z., Tang, Z., & Ren, M. (2025). FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression. Human Mutation. https://doi.org/10.1155/humu/5947612
Vancouver
Han Y, Peng J, Yan W, Wu Z, Tang Z, Ren M. FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression. Human Mutation. 2025. doi:10.1155/humu/5947612
BibTeX
@article{Han2025,
author = {Han, Yu and Peng, Jingxuan and Yan, Wenjie and Wu, Ziqiang and Tang, Zhengyan and Ren, Minghua},
title = {FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression},
journal = {Human Mutation},
year = {2025},
doi = {10.1155/humu/5947612}
}
EUVIMED